Copyright
©The Author(s) 2026.
World J Clin Oncol. Jan 24, 2026; 17(1): 113304
Published online Jan 24, 2026. doi: 10.5306/wjco.v17.i1.113304
Published online Jan 24, 2026. doi: 10.5306/wjco.v17.i1.113304
Table 1 Main characteristics of the whole cohort and the groups with survival, n (%)
| Characteristics | Overall | Survival | Death | P value |
| n | 360 | 151 (41.9) | 209 (58.1) | - |
| Survive time, median (IQR) | 22.2 (12, 38.78) | 38.57 (25.815, 50) | 15 (8.47, 23.17) | < 0.001 |
| Gender | 0.527 | |||
| Male | 287 (79.7) | 118 (32.8) | 169 (46.9) | |
| Female | 73 (20.3) | 33 (9.2) | 40 (11.1) | |
| Age, mean ± SD | 65 (58.75, 70) | 63.649 ± 7.5888 | 64.12 ± 9.497 | 0.602 |
| KPS | 0.006 | |||
| 70 | 6 (1.7) | 0 (0) | 6 (1.7) | |
| 80 | 144 (40) | 50 (13.9) | 94 (26.1) | |
| 90 | 208 (57.8) | 101 (28.1) | 107 (29.7) | |
| 100 | 2 (0.6) | 0 (0) | 2 (0.6) | |
| Smoking history | 0.924 | |||
| No | 142 (39.4) | 60 (16.7) | 82 (22.8) | |
| Yes | 218 (60.6) | 91 (25.3) | 127 (35.3) | |
| Alcohol history | 0.409 | |||
| No | 153 (42.5) | 68 (18.9) | 85 (23.6) | |
| Yes | 207 (57.5) | 83 (23.1) | 124 (34.4) | |
| Tumor location, median (IQR) | 2 (1, 3) | 2 (1, 3) | 2 (2, 3) | 0.036 |
| Clinical stage | < 0.001 | |||
| I | 1 (0.3) | 1 (0.3) | 0 (0) | |
| II | 16 (4.4) | 12 (3.3) | 4 (1.1) | |
| III | 206 (57.2) | 106 (29.4) | 100 (27.8) | |
| IV | 137 (38.1) | 32 (8.9) | 105 (29.2) | |
| RT dose, median (IQR) | 65 (60, 66) | 60 (60, 66) | 66 (60, 66) | 0.001 |
| Chemotherapy | 0.029 | |||
| No | 39 (10.8) | 10 (2.8) | 29 (8.1) | |
| Yes | 321 (89.2) | 141(39.2) | 180 (50) | |
| BMI, median (IQR) | 21.6 (19.947, 23.885) | 22 (20.33, 24.17) | 21.11 (19.53, 23.44) | 0.018 |
| Pre-glucose, median (IQR) | 5.13 (4.71, 5.8225) | 5.03 (4.605, 5.78) | 5.24 (4.77, 5.84) | 0.047 |
| Pre-TC, median (IQR) | 4.725 (4.0475, 5.3625) | 4.82 (4.06, 5.425) | 4.69 (4.01, 5.3) | 0.410 |
| Pre-TG, median (IQR) | 1.13 (0.8975, 1.45) | 1.12 (0.9, 1.45) | 1.13 (0.89, 1.46) | 0.880 |
| Post-BMI, mean ± SD | 20.89 (19.325, 22.58) | 21.537 ± 2.6983 | 20.904 ± 2.6611 | 0.072 |
| Post-glucose, median (IQR) | 5.31 (4.81, 5.94) | 5.26 (4.825, 5.915) | 5.33 (4.8, 5.94) | 0.886 |
| Post-TC, median (IQR) | 4.48 (3.87, 5.29) | 4.64 (4.025, 5.525) | 4.26 (3.73, 5.17) | 0.002 |
| Post-TG, median (IQR) | 1.3 (0.9875, 1.67) | 1.43 (1.1, 1.775) | 1.23 (0.92, 1.53) | < 0.001 |
| PreTyG, median (IQR) | 8.4781 (8.1915, 8.7593) | 8.4357 (8.1754, 8.7729) | 8.5087 (8.207, 8.748) | 0.393 |
| PostTyG, mean ± SD | 9.8787 ± 0.31856 | 9.9299 ± 0.29319 | 9.8418 ± 0.33149 | 0.009 |
| PostTyG-BW, median (IQR) | 82.961 (73.243, 92.833) | 85.855 (74.724, 96.954) | 80.109 (72.236, 89.091) | 0.004 |
| PostTyG-BMI, median (IQR) | 214.85 (195.92, 234.25) | 218.76 (202.14, 237.33) | 211.38 (192.76, 230.09) | 0.006 |
Table 2 Pearson correlation coefficients between post-treatment triglyceride-glucose-related indices and clinical characteristics
| Group | TyG index | Clinical stage | RT dose | Chemotherapy | BMI | Survival time | Survival status | |
| Total patients | PostTyG | R | -0.133 | -0.024 | 0.079 | 0.049 | -0.125 | 0.119 |
| P value | 0.012 | 0.645 | 0.136 | 0.351 | 0.017 | 0.023 | ||
| FDR P value | 0.036 | 0.572 | 0.294 | 0.341 | 0.341 | 0.045 | ||
| PostTyG-BW | R | -0.218 | 0.052 | 0.133 | 0.787 | -0.151 | 0.2 | |
| P value | < 0.001 | 0.329 | 0.012 | < 0.001 | 0.004 | < 0.001 | ||
| FDR P value | 0.739 | 0.572 | 0.739 | 0.163 | 0.501 | 0.402 | ||
| PostTyG-BMI | R | -0.221 | 0.059 | 0.164 | 0.971 | -0.146 | 0.21 | |
| P value | < 0.001 | 0.264 | 0.002 | < 0.001 | 0.005 | < 0.001 | ||
| FDR P value | 0.001 | 0.46 | 0.033 | < 0.001 | 0.014 | 0.033 | ||
| Male | PostTyG | R | -0.19 | -0.016 | 0.096 | 0.075 | -0.115 | 0.142 |
| P value | 0.001 | 0.79 | 0.104 | 0.204 | 0.051 | 0.016 | ||
| FDR P value | 0.008 | 0.615 | 0.196 | 0.341 | 0.288 | 0.112 | ||
| PostTyG-BW | R | -0.245 | 0.072 | 0.174 | 0.821 | -0.163 | 0.257 | |
| P value | < 0.001 | 0.223 | 0.003 | < 0.001 | 0.006 | < 0.001 | ||
| FDR P value | 0.957 | 0.458 | 0.779 | 0.033 | 0.572 | 0.485 | ||
| PostTyG-BMI | R | -0.222 | 0.121 | 0.182 | 0.969 | -0.152 | 0.269 | |
| P value | < 0.001 | 0.04 | 0.002 | < 0.001 | 0.01 | < 0.001 | ||
| FDR P value | 0.002 | 0.288 | 0.033 | < 0.001 | 0.002 | 0.042 | ||
| Female | PostTyG | R | 0.089 | -0.074 | 0.023 | -0.047 | -0.156 | 0.029 |
| P value | 0.453 | 0.535 | 0.849 | 0.691 | 0.187 | 0.807 | ||
| FDR P value | 0.679 | 0.787 | 0.957 | 0.823 | 0.988 | 0.415 | ||
| PostTyG-BW | R | -0.158 | -0.212 | 0.117 | 0.726 | -0.124 | -0.018 | |
| P value | 0.183 | 0.071 | 0.323 | < 0.001 | 0.296 | 0.88 | ||
| FDR P value | 0.453 | 0.779 | 0.79 | 0.558 | 0.739 | 0.572 | ||
| PostTyG-BMI | R | -0.195 | -0.258 | 0.117 | 0.964 | -0.106 | -0.055 | |
| P value | 0.098 | 0.028 | 0.323 | < 0.001 | 0.373 | 0.641 | ||
| FDR P value | 0.458 | 0.447 | 0.558 | < 0.001 | 0.82 | 0.541 | ||
- Citation: Xiao L, Liu YD, Zhang X, Zhang SC, Lyu JH. Post-treatment triglyceride-glucose index as survival protective factors in patients with esophageal squamous cell carcinoma. World J Clin Oncol 2026; 17(1): 113304
- URL: https://www.wjgnet.com/2218-4333/full/v17/i1/113304.htm
- DOI: https://dx.doi.org/10.5306/wjco.v17.i1.113304
